By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Inc. 

900 Davis Drive
P.O. Box 14505
Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-941-6920 Fax: 919-941-6931


SEARCH JOBS
Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: 2600
Symbol: ESALF.PK
 



Industry
Pharmaceutical






Company News
Beyhan Zaim Appointed Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group At Eisai Inc. (ESALF.PK) 4/11/2016 6:39:46 AM
Eisai Inc. (ESALF.PK) Release: Paul Hawthorne Appointed Senior Vice President, U.S. Commercial, Neurology Business Group At Eisai Inc. (ESALF.PK) 4/6/2016 6:29:27 AM
Helsinn Therapeutics (US) Inc. And Eisai Inc. (ESALF.PK) Announce Revised U.S. Collaboration For CINV Franchise 3/18/2016 6:22:09 AM
FDA Approves Eisai Inc. (ESALF.PK)'s Halaven (eribulin mesylate) Injection For The Treatment Of Patients With Advanced Liposarcoma 1/29/2016 6:17:48 AM
Halozyme (HALO) And Eisai Inc. (ESALF.PK) To Present Data Evaluating The Antitumor Effects Of PEGPH20 In Combination With Eribulin Mesylate In Preclinical Breast Cancer Models 12/9/2015 7:48:32 AM
Eisai Inc. (ESALF.PK) Divests Clinical Diagnostics Supply Biz for $183 Million 11/30/2015 8:24:05 AM
Eisai Inc. (ESALF.PK) And Arena (ARNA) Announce FDA Acceptance Of New Drug Application For Extended Release Formulation Of Lorcaserin 11/30/2015 6:50:11 AM
Eisai Inc. (ESALF.PK) Release: Results From Phase 2 Trial Investigating Lenvatinib In Metastatic Renal Cell Carcinoma Published In The Lancet Oncology 10/16/2015 8:03:22 AM
FDA Grants Eisai Inc. (ESALF.PK)'s sNDA For Eribulin Priority Review Designation For The Potential Treatment Of Advanced Soft Tissue Sarcoma 9/28/2015 6:24:37 AM
Eisai Inc. (ESALF.PK) Expands Magnolia Meals At Home Program To Help People Living With Thyroid Cancer 9/25/2015 10:48:13 AM
12345678910...
//-->